SEATTLE, UNITED STATES, UNITED STATES, February 4, 2022 /EINPresswire.com/ -- New Research Study "Candidiasis Market 2022 analysis by Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges and Investment Opportunities), Size, Share and Outlook" has been added to Coherent Market Insights.

Growing focus on inorganic growth strategies such as mergers and acquisitions is expected to drive growth of the global candidiasis market during the forecast period. For instance, in March 2018, NovaQuest Capital Management L.L.C. acquired Viamet Pharmaceuticals (NC), Inc., which included the company's product candidate, VT-1161, which successfully completed Phase 2b clinical trials. The product is indicated for the treatment of recurrent vulvovaginal candidiasis and onychomycosis (fungal nail infection). Moreover, in 2014, NovaDigm Therapeutics acquired the rights to three Candida vaccine antigens from the Los Angeles BioMedical Research Institute at Harbor-UCLA Medical Center, which significantly strengthened the company's candida vaccine pipeline.

Request For A Sample Report @ https://www.coherentmarketinsights.com/insight/request-sample/229

Furthermore, rising emphasis on research and development activities, in order to cater to unmet needs is expected to propel the global candidiasis market growth over the forecast period. For instance, in August 2019, researchers from the Los Angeles Biomedical Research Institute (LA BioMed), a spinoff company of NovaDigm Therapeutics, started developing the vaccine-NDV-3A to prevent infections caused by C. auris in humans, after successfully immunizing and demonstrating its clinical efficacy in mice. Moreover, in 2017, the University Hospital of Cologne initiated a clinical trial to evaluate drug candidate SCY-078 in patients with fungal diseases that are refractory to or intolerant of standard antifungal treatment, in Europe.

Key Takeaways

• The global candidiasis market is expected to witness significant growth, exhibiting a CAGR of 4.5% over the forecast period. This is owing to increasing incidence of candidiasis infection and rising number of mergers and acquisitions by key companies.

• On the basis of drug class, the azoles segment accounted for the largest share in 2017, since azoles are considered as the first-line agents in the treatment of various types of candidiasis such as esophageal and vaginal candidiasis.

• On the basis of type, the vaginal candidiasis segment held a major market share in 2017, owing to increasing research and development activities for product development in this segment.

• On the basis of administration, the oral segment held a higher market share in 2017, as several antifungal drugs used for the treatment and management of candidiasis are available in oral dosage form.

• Key companies involved in the global candidiasis market are Basilea Pharmaceutica Ltd., Astellas Pharma Inc., Grupo Ferrer Internacional, S.A., Pacgen Life Science Corporation, NovaDigm Therapeutics, Inc., Cidara Therapeutics, Inc., Amplyx Pharmaceuticals Inc., and Pfizer, Inc.

Buy This Complete Business Report With Flat USD 2000 Off @
https://www.coherentmarketinsights.com/promo/buynow/229

The following are the study objectives for this report:

· SWOT Analysis focuses on worldwide main manufacturers to define, assess, and analyse market competition. By kind, application, and region, the market is defined, described, and forecasted.
· Examine the global and main regional market potential and advantage, opportunity and challenge, constraints and risks.
· Determine whether trends and factors are driving or limiting market growth.
· By identifying high-growth categories, stakeholders would be able to analyse market potential.
· Conduct a strategic study of each submarket's growth trends and market contribution.
· Expansions, agreements, new product launches, and acquisitions in the market are all examples of competitive developments.
· To create a strategic profile of the main players and analyse their growth plans in depth.

Mr.Shah
Coherent Market Insights
+1 2067016702
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.